“We have excellent cooperation opportunities with universities in Hong Kong and Macau.” Max Wang, Ph.D., Co-Founder and Senior Vice President of Akesobio, told us. “We will expand our cooperation with Hong Kong and promote our clinical trials and even commercialization of our medicines in Hong Kong.”  

As a pioneer and promoter of biopharma innovation in China, Akesobio has been committed to the independent discovery, development and commercialization of pioneering new drugs and similar best antibody biologics since its establishment in 2012, providing high-quality innovative antibody drugs to patients around the world. Through Chapter 18A, Akesobio was listed on HKEX in April, 2020.

In March this year, Akesobio Bay Area Science and Technology Park is put into use in Chui Heng New District, Zhongshan, which is only a few miles from the ShenZhong Link that is about to open in June. 

策划：于晓娜

记者：袁思杰 实习生杨梓昊

监制：朱丽娜

编辑：胡慧茵 朱丽娜

视频制作：袁思杰

出品：南方财经全媒体集团 国际传播中心